Are ACE inhibitors and ARBs more beneficial than harmful in the treatment of severe COVID-19 disease?
Article Sidebar
Main Article Content
Downloads
Article Details
Copyright (c) 2020 Devaux CA.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Zhu N, Zhang D, Wang W, Li X, Yang B, et al. (2019) A Novel Coronavirus from Patients with Pneumonia in China. N Engl J Med 382: 727-733. Link: https://bit.ly/2VYaBji
Huang C, Wang Y, Li X, Ren L, Zhao J, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506. Link: https://bit.ly/2z3ffUe
Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8: e21. Link: https://bit.ly/3fj1h0P
Yan R, Zhang Y, Li Y, Xia L, Guo Y, et al. (2020) Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science 367: 1444-1448. Link: https://bit.ly/2xvhUFC
Bavishi C, Maddox TM, Messerli FH (2020) Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiol. Link: https://bit.ly/2WspXeM
Sparks M, Hiremath S (2020) The Coronavirus Conundrum: ACE2 and hypertension edition. NephJC. Link: https://bit.ly/3c2dsgK
Glowacka I, Bertram S, Herzog P, Pfefferle S, Steffen I, et al. (2010) Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63. J Virol 84: 1198-1205. Link: https://bit.ly/3b2G0VQ
Kuba K, Imai Y, Rao S, Gao H, Guo F, et al. (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Med 11: 875-879. Link: https://bit.ly/3fqVW82
Wang PH, Cheng Y (2020) Increasing host cellular receptor-angiotensin-converting enzyme 2 (ACE2) expression by coronavirus may facilitate 2019-nCoV infection. Link: https://bit.ly/3bWYxEq
Diez-Freire C, Vazquez J, Correa de Adjounian MF, et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics 27: 12-19. Link: https://bit.ly/2yrz8UN
Tikellis C, Pickering R, Tsorotes D, Du XJ, Kiriazis H, et al. (2012) Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. Clin Sci 123: 519-529. Link: https://bit.ly/2WnvC5T
Velkoska E, Patel SK, Burrell LM (2016) Angiotensin converting enzyme 2 and diminazene: role in cardiovascular and blood pressure regulation. Curr Opin Nephrol Hypertens 25: 384-395. Link: https://bit.ly/3fjAYrk
Tallant EA, Clark MA (2003) Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 42: 574-579. Link: https://bit.ly/3deyVDq
Pena Silva RA, Chu Y, Miller JD, Mitchell IJ, Penninger JM, et al. (2012) Impact of ACE2 deficiency and oxidative stress on cerebrovascular function with aging. Stroke 43: 3358-3363. Link: https://bit.ly/3b7wOjn
Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8258-8263. Link: https://bit.ly/2VYOjOg
Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, et al. (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417: 822–828. Link: https://bit.ly/2SA1tiy
Erdos EG, Skidgel RA (1987) The angiotensin I-converting enzyme. Lab Invest 56: 345-348.
Hunyady L, Catt KJ (2006) Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II. Mol Endocrinol 20: 953-970. Link: https://bit.ly/2yoxdAt
Carluccio M, Soccio M, De Caterina R (2001) Aspects of gene polymorphisms in cardiovascular disease : the renin-angiotensin system. Eur J Clin Invest 31: 476-488. Link: https://bit.ly/2WmO1zH
Vuille-dit-Bille RN, Camargo SM, Emmenegger L, Sasse T, Kummer E, et al. (2015) Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids 47: 693-705. Link: https://bit.ly/2VYcQTK
Devaux CA, Rolain JM, Raoult D (2020) ACE2 receptor polymorphism : susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Inf. Link: https://bit.ly/2yuoQ6F
Yang X, Yu Y, Xu J, Shu H, Xia J, et al. (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. Link: https://bit.ly/2YyfMIi
Rapid risk assessment (2020) Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK– ninth update. Link: https://bit.ly/3aUqrja
CDC (2020) CDC, Washington State report first COVID-19 death. Atlanta, GA: US Department of Health and Human Services. Link: https://bit.ly/2yfBMgA